

Y. Ikeura, et al  
U.S.S.N. 09/807,337  
Page 2

RECEIVED  
CENTRAL FAX CENTER  
JUL 11 2006

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

- 1-3. (Cancelled).
4. (Currently amended) A base for a percutaneously absorbing preparation, wherein ~~comprising styrene-isoprene-styrene block copolymer and/or polyisobutylene, softener, and tackifier, are essential components and hexylene glycol and 1-menthol are sorbefacients as the components of the base, wherein 10-40% by weight of styrene-isoprene-styrene block copolymer, 2-10% by weight of polyisobutylene, 10-60% by weight of softener and 20-60% by weight of tackifier are essential components, and 1-10% by weight of hexylene glycol and 0.1-7% by weight of 1-menthol are compounded therewith as the components of the base.~~
5. (Cancelled)
6. (Currently amended) A percutaneously absorbing preparation wherein a pharmaceutical agent is contained as an effective ingredient in the base for a percutaneously absorbing preparation ~~according to claim 4 mentioned in claims 4 to 5.~~
7. (Previously Presented) The percutaneously absorbing preparation according to claim 6, wherein the pharmaceutical agent is follicular hormone and/or luteinizing hormone.
8. (Original) The percutaneously absorbing preparation according to claim 7, wherein the follicular hormone is estradiol or a derivative thereof and its compounding amount is 0.1-5% by weight.
9. (Withdrawn) The percutaneously absorbing preparation according to claim 7, wherein

Y. Ikura, et al  
U.S.S.N. 09/807,337  
Page 3

the luteinizing hormone is norethisterone, norethisterone acetate or a derivative thereof and its compounding amount is 0.5-10% by weight.